Tibet Rhodiola Pharmaceutical Holding Co (600211) Stock Price & News

Symbols Symbols	Price	Change	% Change	Trend	Prev Close	Open	High	Low	Volume	Mkt Cap
SIXB Materials SIXB Materials	SIXB -0.07%	1,101.37	-0.81	-0.07%	—	1,102.18	1,096.24	1,103.05	1,090.35	—	—
SIXC Communications SIXC Communications	SIXC -0.47%	613.35	-2.89	-0.47%	—	616.24	616.24	617.68	609.10	—	—
SIXE Energy SIXE Energy	SIXE +0.77%	1,198.83	+9.11	+0.77%	—	1,189.72	1,194.74	1,202.79	1,188.58	—	—
SIXI Industrials SIXI Industrials	SIXI +1.75%	1,755.95	+30.26	+1.75%	—	1,725.69	1,730.02	1,762.99	1,730.02	—	—
SIXM Financials SIXM Financials	SIXM -0.79%	638.51	-5.11	-0.79%	—	643.62	643.13	643.17	632.59	—	—
SIXR Staples SIXR Staples	SIXR +1.65%	843.52	+13.73	+1.65%	—	829.79	832.32	845.25	832.32	—	—
SIXRE Real estate SIXRE Real estate	SIXRE +1.19%	215.95	+2.55	+1.19%	—	213.40	213.40	216.07	213.40	—	—
SIXT Technology SIXT Technology	SIXT -1.48%	3,138.91	-47.01	-1.48%	—	3,185.92	3,160.89	3,178.72	3,102.60	—	—
SIXU Utilities SIXU Utilities	SIXU +2.80%	934.37	+25.43	+2.80%	—	908.94	912.57	934.91	912.57	—	—
SIXV Health care SIXV Health care	SIXV -0.10%	1,477.43	-1.53	-0.10%	—	1,478.96	1,478.17	1,482.91	1,466.65	—	—
SIXY Discretionary SIXY Discretionary	SIXY -1.05%	2,380.19	-25.17	-1.05%	—	2,405.36	2,390.34	2,402.53	2,359.18	—	—

600211:SHA

Tibet Rhodiola Pharmaceutical Holding Co

CN¥40.83

-0.39%

(-0.16) 1D

Apr 24, 2:53:25 PM GMT+8 · CNY

All symbols

YTD

MAX

	Symbol	Price	Change	% Change

Generating top insights for 600211...

Open

CN¥40.92

High

CN¥41.19

Low

CN¥40.71

Mkt. cap

13.33B

Avg. vol.

3.47M

Volume

1.44M

P/E ratio

14.03

52-wk high

CN¥57.98

52-wk low

CN¥34.93

EPS

CN¥2.91

Shares outstanding

179.62M

No. of employees

671

Related stocks

600332

Guangzhou Baiyunshan Pharmaceutical Holdings Ord Shs A

CN¥22.54

-0.57%

600285

Henan Lingrui Pharmaceutical Co., Ltd.

CN¥21.56

+0.56%

600329

Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd

CN¥39.83

-1.31%

002727

Yixintang Pharmaceutical Co Ltd

CN¥12.56

-1.10%

News stories

From sources across the web

Macau Business

5 minutes ago

NYSE Content Update: NYSE to Host ‘Ring the Bell for Financial Literacy’

Moomoo

1 hour ago

$S&P 500 Index (.SPX.US)$ $SPDR S&P 500 ETF (SPY.US)$ [Share Link: Chart of the Day ]📈[Share Link: S&P 500 extends gains, supported by CTA fund buying | XTB] In recent weeks, gains in the S&P 500 appear to be significantly driven by buying activity fr

FOX 2

2 hours ago

Asian stocks slip, tracking Wall Street losses, and Iran war doubts push oil higher

Reuters

2 hours ago

Up, or down? War scrambles financial markets' signalling efforts

About Tibet Rhodiola Pharmaceutical Holding Co

CEO-

Employees671

FoundedJul 14, 1999

Headquarters-

SectorHealth care provider

Websitexzyy.cn

All values in CNY	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Revenue	712.11M	938.60M	438.57M	892.27M
Cost of goods sold	37.34M	52.39M	41.19M	41.01M
Cost of revenue	37.34M	52.39M	41.19M	41.01M
Research and development expenses	5.28M	13.50M	9.35M	45.96M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	413.54M	541.93M	248.18M	569.90M
Operating expense	425.87M	570.96M	218.72M	669.38M
Total operating expenses	463.22M	623.35M	259.91M	710.39M
Operating income	248.89M	315.24M	178.66M	181.87M
Other non operating income	2.80M	-2.86M	1.73M	-1.78M
EBT including unusual items	301.65M	335.67M	173.13M	230.16M
EBT excluding unusual items	292.98M	328.77M	191.14M	188.37M
Income tax expense	31.40M	35.13M	18.02M	39.09M
Effective tax rate	10.41%	10.47%	10.41%	16.98%
Other operating expenses	7.06M	14.74M	-38.78M	54.69M
Net income	269.28M	298.04M	154.45M	216.15M
Net profit margin	37.81%	31.75%	35.22%	24.23%
Earnings per share	-	-	-	-
Interest and investment income	41.29M	14.48M	14.86M	17.37M
Interest expense	-	-148.31K	-2.04M	-10.40M
Net interest expenses	41.29M	14.33M	12.82M	6.97M
Depreciation and amortization charges	-	-	-	-
EBITDA	267.44M	333.34M	197.21M	201.24M
Gain or loss from assets sale	-	-152.70K	152.70K	-108.68K

AI content may include mistakes. Learn more

HelpSend feedbackPrivacy Terms Disclaimer

Finance

Research